home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
HaCKeRz KrOnIcKLeZ 3
/
HaCKeRz_KrOnIcKLeZ.iso
/
drugs
/
mdma.neurotoxic.info
< prev
next >
Wrap
Internet Message Format
|
1996-05-06
|
5KB
From: lamont@hyperreal.com (Lamont Granquist)
Newsgroups: alt.drugs
Subject: New info on MDMA neurotoxicity
Date: 1 Apr 1994 21:57:24 GMT
Message-ID: <2ni5c4$nq1@news.u.washington.edu>
this is from my e-mail (fwd w/permission)...
From rickmaps@aol.com Fri Apr 1 13:54:00 1994
>Date: Fri, 01 Apr 94 00:21:22 EST
>From: rickmaps@aol.com
>To: lamont@hyperreal.com
>Subject: Re: MDMA References
>
>Lamont,
>
>You already have virtually all the essential information. The Ricaurte
>primate study is unpublished, so its not surprising that you didn't find
>anything written about it. Here is the section of the IND application Sasha
>referred to:
>
>Ricaurte (personal communication,1992) and associates at Johns Hopkins
>University recently completed the data analysis portion of a primate study
>which for the first time has identified a no-effect level for MDMA
>neurotoxicity. The study involved six primates, three controls and three
>experimental animals who received an oral administration of 2.5 mg/kg of MDMA
>once every two weeks for four months (8x). Eight brain regions were examined
>for 5-HT and 5-HIAA content. There were no significant differences between
>experimental and control animals in any of the brain regions studied. Since a
>previous study by Ricaurte (1988a) has shown that a single oral dose of 5.0
>mg/kg causes neurotoxicity only in the thalamus and hypothalamus, this
>study demonstrates that the primate no-effect level lies somewhere between
>2.5 and 5.0 mg /kg.
>
>Here is something else from that application:
>
>H
>uman study of response of MDMA users to DMT
>
> Strassman (personal communication,1992) recently completed an FDA-approved
>human study in which the physiological and psychological responses of ele
>ven subjects to various i.v. doses of DMT were studied. Physiological
>measures included x-endorphin, ACTH, prolactin, corticol, growth hormone,
>baseline and maximum rise temperature and pupil diameter responses.
>Psychological measures included the Profile of Mood States (POMS) and the
>Hallucinogenic Rat
>ing Scale (HRS) developed specifically for this experiment.
>
> Subjects were divided in
>to two groups, "MDMA Positive" and "MDMA Negative". The "MDMA Positive"
>group included six subjects who had taken MDMA five or more times. Not
>including one of those had taken MDMA 75
>-100 times, the average exposure for the "MDMA Positive" group was about
>10x. The "MD
>MA Negative" group included the remaining five subjects had taken MDMA never
>or only once, with an
>average exposure of less than 1x.
>
> Analysis of the physiological measurements revealed no
> significant differences between the groups in x-endorphin, ACTH, prolactin,
>corticol, growth hormone, baseline and maximum rise temperature responses,
>across all four doses of DMT and placebo. The standard analytic tool was
>ANOVA with repeated measures. The only significant difference between the "
>MDMA Positive" and "MDMA Negative" groups was that the maximum change in
>pupil diameter relative to baseline was less in the positives than the
>negatives, across all doses of drug/placebo.
> Dr. Strassman noted "If one believes that 5-HT2 receptors in the eye
>mediate the effect of DMT
>on pupil size, then this is oppostive what one would expect; i.e. if
>"denervation hypersensitivity"
> occurred, one would expect more robust pupil dilation. The pupil data was
>the least complete (people were reluctant to open their eyes during the
>period of DMT intoxication), thus ANOVA without repea
>ted measurements was used as a less than ideal tool."
>
> Analysis of the psychological data showed no significant differences in the
>POMS given both before and after the injections of DMT. Rega
>rding the HRS, no differences were noted in responses for any of the 6
>factors between the "MDMA P
>ositive" and "MDMA Negative" groups across all doses of DMT/placebo; neither
>were there any interaction effects.
>
>
>The most important paper you have missed is by O'Callaghan, in NIDA
>Monograph # 136, Assessing Neurotoxicity of Drugs of Abuse. Its available for
>free from the National Clearinghouse for Alcohol and Drug Information (301)
>468-2600, or 800 729-6686. The paper discusses data that suggests that
>lowered serotonin levels do not always reflect neurotoxicity.
>
>Also, have you seen Charlie Grob's paper in Journal of Nervous and Mental
>Disease, Vol. 180, No. 6, June, 1992, p. 345-356 ?
>
>I'd be curious to learn of your estimation of the neurotoxic risk of MDMA.
>
>Also, in case you are interested you are invited to join MAPS. The address
>is 1801 Tippah Avenue, Charlotte, NC 28205, and general memberships are $30
>or more. The latest newsletter is at the printers and will be send out to
>members in the next few weeks. Since earlier today, MAPS can accept credit
>card orders.
>
>Rick Doblin
>
>